Estratificação da Insuficiência Cardíaca Clínica através do Mapa T1 Nativo: Experiência de um Serviço de Referência

BACKGROUND Diffuse cardiac fibrosis is an important factor in the prognostic assessment of patients with ventricular dysfunction. Cardiovascular magnetic resonance imaging (CMR) native T1 mapping is highly sensitive and considered an independent predictor of all-cause mortality and heart failure (HF) development in patients with cardiomyopathy. OBJECTIVES To evaluate the feasibility of native T1 mapping assessment in patients with HF in a cardiology referral hospital and its association with structural parameters and functional profile. METHODS Cross-sectional study with adult patients with HF NYHA functional classes I and II, ischemic and non-ischemic, followed in a referral hospital, who underwent CMR. Native T1 values were analyzed for structural parameters, comorbidities, etiology, and categorization of HF by left ventricular ejection fraction (LVEF). Analyses were performed with a significance level of 5%. RESULTS Enrollment of 134 patients. Elevated native T1 values were found in patients with greater dilation (1004.9 vs 1042.7ms, p = 0.001), ventricular volumes (1021.3 vs 1050.3ms, p <0.01) and ventricular dysfunction (1010.1 vs 1053.4ms, p <0.001), also present when the non-ischemic group was analyzed separately. Patients classified as HF with reduced ejection fraction had higher T1 values than those with HF and preserved ejection fraction (HFPEF) (992.7 vs 1054.1ms, p <0.001). Of those with HFPEF, 55.2% had higher T1. CONCLUSIONS CMR T1 mapping is feasible for clinical HF evaluation. There was a direct association between higher native T1 values and lower ejection fraction, and with larger LV diameters and volumes, regardless of the etiology of HF.

[1]  C. Rochitte,et al.  Long-Term Prognostic Value of Myocardial Fibrosis in Patients With Chagas Cardiomyopathy. , 2018, Journal of the American College of Cardiology.

[2]  Richard B. Thompson,et al.  Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI) , 2017, Journal of Cardiovascular Magnetic Resonance.

[3]  Jie Zheng,et al.  A non-contrast CMR index for assessing myocardial fibrosis. , 2017, Magnetic resonance imaging.

[4]  Stefan K. Piechnik,et al.  Measurement of myocardial native T1 in cardiovascular diseases and norm in 1291 subjects , 2017, Journal of Cardiovascular Magnetic Resonance.

[5]  A. Tajik,et al.  Modern Imaging Techniques in Cardiomyopathies. , 2017, Circulation research.

[6]  Virginia W. Lesslie,et al.  Cardiac Magnetic Resonance T1-Mapping of the Myocardium: Technical Background and Clinical Relevance. , 2017, Journal of thoracic imaging.

[7]  Helena Antić,et al.  Myocardial tissue characterization by magnetic resonance imaging , 2017 .

[8]  D. Bluemke,et al.  Normal values for cardiovascular magnetic resonance in adults and children , 2015, Journal of Cardiovascular Magnetic Resonance.

[9]  N. Yamada,et al.  Prognostic impact of blood pressure response plus gadolinium enhancement in dilated cardiomyopathy , 2015, Heart.

[10]  H. Hayashi,et al.  Distribution of late gadolinium enhancement in various types of cardiomyopathies: Significance in differential diagnosis, clinical features and prognosis. , 2014, World journal of cardiology.

[11]  M. Robson,et al.  Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement , 2013, Journal of Cardiovascular Magnetic Resonance.

[12]  M. Robson,et al.  Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. , 2013, JACC. Cardiovascular imaging.

[13]  D. Burkhoff,et al.  Myocardial recovery and the failing heart: myth, magic, or molecular target? , 2012, Journal of the American College of Cardiology.

[14]  Maria Drangova,et al.  Prediction of Arrhythmic Events in Ischemic and Dilated Cardiomyopathy Patients Referred for Implantable Cardiac Defibrillator: Evaluation of Multiple Scar Quantification Measures for Late Gadolinium Enhancement Magnetic Resonance Imaging , 2012, Circulation. Cardiovascular imaging.

[15]  João A. C. Lima,et al.  Realce Tardio Miocárdico por Ressonância Magnética Cardíaca pode Identificar Risco para Taquicardia Ventricular na Cardiopatia Chagásica Crônica Delayed Enhancement Cardiac Magnetic Resonance Imaging can Identify the Risk for Ventricular Tachycardia in Chagas' cardiomyopathy , 2012 .

[16]  Stefan Neubauer,et al.  Shortened Modified Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold , 2010, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[17]  H. Kestler,et al.  Electrocardiographic and cardiac magnetic resonance imaging parameters as predictors of a worse outcome in patients with idiopathic dilated cardiomyopathy , 2009, European heart journal.

[18]  H. Sakuma,et al.  Native T1 Mapping and Extracellular Volume Mapping for the Assessment of Diffuse Myocardial Fibrosis in Dilated Cardiomyopathy. , 2018, JACC. Cardiovascular imaging.

[19]  E. Nagel,et al.  T1-Mapping and Outcome in Nonischemic Cardiomyopathy: All-Cause Mortality and Heart Failure. , 2016, JACC. Cardiovascular imaging.

[20]  D. Kaye,et al.  Histological validation of cardiac magnetic resonance analysis of regional and diffuse interstitial myocardial fibrosis. , 2015, European heart journal cardiovascular Imaging.

[21]  Mark T. Waters,et al.  This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits distribution,andreproductioninanymedium,providedtheoriginalauthorandsourcearecredited.Thislicensedoesnot permit commercial exploitation or the creation of derivative works without sp , 2009 .

[22]  M. Friedrich,et al.  Magnetic Resonance of Cardiomyopathies and Myocarditis , 2008 .

[23]  C. Long,et al.  The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. , 2005, Annual review of pharmacology and toxicology.